FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

0140	4 DDD 0\ (4.1
OMB	APPROVAL

OMB Number: 3235-0287 Estimated average burden

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SIGMA TAU INTERNATIONAL SA (Last) (First) (Middle)			2. Issuer Name and Ticker or Trading Symbol QUESTCOR PHARMACEUTICALS INC [QSC]						Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title Other (specify below) below)				
(Last) (First) (Middle) 18 AVENUE DE LA PORTE NEUVE			ee of Earliest Trans 5/2005	Month	/Day/Year)		DEIOW)		neiow)				
(Street) LUXEMBOURG N4 L-2227			4. If Amendment, Date of Original Filed (Month/Day/Year)						Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person				
(City) (State) (Zip)													
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction 2. Transaction 2. Deemed 3. 4. Securities Acquired (A) or 5. Amount of 6. Ownership 7. Nat													
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/		Execution Date,		ction Instr.	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5			5. Amount of Securities Beneficially Owned Followi Reported	6. Owners Form: Dir (D) or Ind (I) (Instr. 4	ect Indir	eficial ership	
				Code	٧	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				
Common Stock, no par value per share									8,643,397	7 D			
Common Stock, no par value per share									1,756,781	1 I	by (res ectly held Claudio vazza. ⁽¹⁾	
Common Stock, no par value per share									1,756,782	2 I	by I	res ectly held Paolo vazza. ⁽¹⁾	
Common Stock, no par value per share									759,493	I	by I Fan	res ectly held Defiante maceutica .A. ⁽¹⁾	
Common Stock, no par value per share									549,100	I	by A	res ectly held Aptafin A. ⁽¹⁾	
Common Stock, no par value per share									100,000	I	by Cha Cor & S SD0 Uni	ectly held numiere - nsultadoria dervicos	
Common Stock, no par value per share	04/15/2	005		J ⁽²⁾		1,265,822	D	(2)	0	I	the Cor Deb held Def Farr	erlying 8% avertible benture	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)													
1. Title of Derivative Conversion Date Sacution Date A. December 4. Transcription Date, Date, Date, Date,		saction 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration I (Month/Day		cisable and ate Year)	7. Title and Amount of Securities Underlyin Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
	Code	e V	(A) (D)	Date Exerci	sable	Expiration Date	Title	Amount of Number of Shares	·	(Instr. 4)			

			(e	.g., pı	ıts, c	alls	, warrants	s, options,	converti	ble secu	ırities)				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Deri Sec Acq Dis	umber of vative urities uired (A) or oosed of (D) tr. 3, 4 and	6. Date Exerc Expiration Da (Month/Day/V	ite	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
8% Convertible Debenture	\$1.58	04/15/2005		J ⁽⁴⁾			\$2,000,000	(3)	04/15/2005	Common Stock, no par value per share	1,265,822	\$2,000,000	\$0	I	The 8% Convertibl Debenture was directl held by Defiante Farmaceut L.d.A.(1)

				Code	V				
8% Convertible Debenture	\$1.58	04/15/2005		J ⁽⁴⁾					
Name and Address of Reporting Person* SIGMA TAU INTERNATIONAL SA									
(Last) (First) (Middle) 18 AVENUE DE LA PORTE NEUVE									
(Street)	L-2227								
(City)		(State)	(Zip)						
l		Reporting Person* NANZIARIA	<u>SPA</u>						
(Last) VIA SUE 144	OAFRICA 2	(First)	(Middle)	(Middle)					
(Street)	(Street) ROME ITALY								
(City)		(State)	(Zip)						
1. Name and Address of Reporting Person* <u>DEFIANTE FARMACEUTICA LDA</u>									
(Last) RUA DO	S FERREIF	(First) ROS,260	(Middle)						
(Street) FUNCHA MADEIR		9000-082	2						
(City)		(State)	(Zip)						
Name and Address of Reporting Person* APTAFIN S P A									
(Last) VIALE S	HAKESPE.	(Middle)							
(Street)		00144	00144						
(City)		(Zip)							
Name and Address of Reporting Person* CAVAZZA CLAUDIO									
(Last) VIA SUE	OAFRICA 2	(Middle)							
(Street)	TALY	00000							
(City)	(City) (State) (Zip)								
4 No		*							

1. Name and Address of Reporting Person*

AOLO		
(First)	(Middle)	
ГЕ, 10		
V8	V8	
(State)	(7in)	
	(First)	(First) (Middle) FE, 10 V8 V8

Explanation of Responses:

1. Sigma-Tau Finanziaria S.p.A. owns 100% of the capital stock of Sigma-Tau International S.A. (f/k/a Sigma-Tau Finance Holding S.A.) and 58% of the capital stock of Defiante Farmaceutica L.d.A. Sigma-Tau International S.A. owns 42% of the capital stock of Defiante Farmaceutica L.d.A. Claudio Cavazza owns, directly and indirectly, 60% of Sigma-Tau Finanziaria S.p.A. and Paolo Cavazza owns, directly and indirectly, 40% of Sigma-Tau Finanziaria S.p.A. Paolo Cavazza also owns, directly and indirectly, 100% of Aptafin S.p.A. Aptafin S.p.A. owns, directly and indirectly, 100% of Chaumiere - Consultadoria & Servicos SDC Unipessoal LDA

- $2. \ The shares were underlying the 8\% \ Convertible \ Debenture \ held \ by \ Defiante \ Farmaceutica \ L.d.A., \ which \ matured \ on \ April \ 15, \ 2005.$
- 3. The 8% Convertible Debenture held by Defiante Farmaceutica L.d.A. was convertible into Common Stock, no par value per share, at any time prior to the maturity date of April 15, 2005.
- 4. The 8% Convertible Debenture matured on April 15, 2005. Questcor Pharmaceuticals Inc. has advised Defiante Farmaceutica L.d.A. that the debenture will be repaid in full.

Maurizio Terenzi, Attorney-in- fact for Sigma-Tau International S.A.	04/19/2005
Maurizio Terenzi, Attorney-in- fact for Sigma-Tau Finanziaria S.p.A.	04/19/2005
Maurizio Terenzi, Attorney-in- fact for Defiante Farmaceutica L.D.A.	04/19/2005
Maurizio Terenzi, Attorney-in- fact for Aptafin S.p.A.	04/19/2005
Maurizio Terenzi, Attorney-in- fact for Chaumiere - Consultadoria & Servicos SDC Unipessoal LDA	04/19/2005
Maurizio Terenzi, Attorney-in- fact for Claudio Cavazza	04/19/2005
<u>Maurizio Terenzi, Attorney-in-</u> <u>fact for Paolo Cavazza</u>	04/19/2005
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.